Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Oct;197(10):939-942.
doi: 10.1007/s00066-021-01825-x. Epub 2021 Sep 2.

[Radiation therapy in high-risk and very high-risk localized or locally advanced prostate cancer : Prostate-only versus prostate plus whole-pelvic?]

[Article in German]
Martin Stuschke  1 , Boris Hadaschik  2
Affiliations
Comment

[Radiation therapy in high-risk and very high-risk localized or locally advanced prostate cancer : Prostate-only versus prostate plus whole-pelvic?]

[Article in German]
Martin Stuschke et al. Strahlenther Onkol. 2021 Oct.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Roach M, Moughan J, Lawton CAF, et al. Sequence of hormonal therapy and radiation field size in unfavourable, localized prostate cancer (NRG/RTOG 9413): long-term results of a randomized, phase 3 trial. Lancet Oncol. 2018;19:1504–1515. doi: 10.1016/S1470-2045(18)30528-X. - DOI - PMC - PubMed
    1. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUC-01. J Clin Oncol. 2007;25:5366–5373. doi: 10.1200/JCO.2006.10.5171. - DOI - PubMed
    1. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF) (2019) Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043/022OL. http://www.leitlinienprogramm-onkolo-gie.de/leitlinien/prostatakarzinom/. Zugegriffen: 24. Apr. 2021
    1. Xie W, Regan MM, Buyse M, et al. Event-free survival, a prostate-specific-antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation. J Clin Oncol. 2020;38:3032–3042. doi: 10.1200/JCO.19.03114. - DOI - PMC - PubMed
    1. Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomized, non-inferiority, phase 3 trial. Lancet. 2019;394:385–395. doi: 10.1016/S0140-6736(19)31131-6. - DOI - PubMed

Substances